CN113677366A - 用于治疗克罗恩氏病的方法中的米吉珠单抗 - Google Patents

用于治疗克罗恩氏病的方法中的米吉珠单抗 Download PDF

Info

Publication number
CN113677366A
CN113677366A CN202080030747.5A CN202080030747A CN113677366A CN 113677366 A CN113677366 A CN 113677366A CN 202080030747 A CN202080030747 A CN 202080030747A CN 113677366 A CN113677366 A CN 113677366A
Authority
CN
China
Prior art keywords
weeks
administered
dose
treating
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080030747.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·W·弗里德里希
P·F·波拉克
J·L·塔特尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to CN202411949868.6A priority Critical patent/CN119700968A/zh
Publication of CN113677366A publication Critical patent/CN113677366A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202080030747.5A 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗 Pending CN113677366A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411949868.6A CN119700968A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962836910P 2019-04-22 2019-04-22
US62/836910 2019-04-22
PCT/US2020/028273 WO2020219314A1 (en) 2019-04-22 2020-04-15 Mirikizumab for use in a method of treating crohn's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411949868.6A Division CN119700968A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Publications (1)

Publication Number Publication Date
CN113677366A true CN113677366A (zh) 2021-11-19

Family

ID=70554215

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080030747.5A Pending CN113677366A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗
CN202411949868.6A Pending CN119700968A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411949868.6A Pending CN119700968A (zh) 2019-04-22 2020-04-15 用于治疗克罗恩氏病的方法中的米吉珠单抗

Country Status (16)

Country Link
US (1) US20220040299A1 (https=)
EP (1) EP3958897A1 (https=)
JP (3) JP7297930B2 (https=)
KR (2) KR102869852B1 (https=)
CN (2) CN113677366A (https=)
AU (2) AU2020263238C1 (https=)
BR (1) BR112021018930A2 (https=)
EA (1) EA202192532A1 (https=)
IL (2) IL286818B2 (https=)
MA (1) MA55756A (https=)
MX (1) MX2021012848A (https=)
SG (1) SG11202110619XA (https=)
TW (2) TW202515610A (https=)
UA (1) UA128657C2 (https=)
WO (1) WO2020219314A1 (https=)
ZA (1) ZA202108094B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法
KR20220066831A (ko) 2020-11-16 2022-05-24 엔브이에이치코리아(주) 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170081402A1 (en) * 2015-09-18 2017-03-23 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2019012531A1 (en) * 2017-07-10 2019-01-17 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODY RATES IN BIOLOGICAL DRUG SUBJECTS AND USES THEREOF IN A CUSTOMIZED MEDICINE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR094877A1 (es) 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
KR20150128859A (ko) 2013-03-15 2015-11-18 암젠 인크 항-il23 항체를 사용하여 크론병을 치료하는 방법
WO2018035330A1 (en) * 2016-08-19 2018-02-22 Janssen Biotech, Inc. Methods of treating crohn's disease with an anti-nkg2d antibody
TW202515610A (zh) * 2019-04-22 2025-04-16 美商美國禮來大藥廠 治療克隆氏症(crohn's disease)的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170081402A1 (en) * 2015-09-18 2017-03-23 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
WO2019012531A1 (en) * 2017-07-10 2019-01-17 Rambam Med-Tech Ltd. ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODY RATES IN BIOLOGICAL DRUG SUBJECTS AND USES THEREOF IN A CUSTOMIZED MEDICINE

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHRISTOPHERS MA等: "Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn\'s disease", 《EXPERT OPINION ON INVESTIGATIONAL DRUGS》, vol. 27, no. 8, pages 649 - 660, XP055711425, DOI: 10.1080/13543784.2018.1506764 *

Also Published As

Publication number Publication date
EA202192532A1 (ru) 2022-01-21
JP2025148449A (ja) 2025-10-07
KR20210142704A (ko) 2021-11-25
IL324048A (en) 2025-12-01
MX2021012848A (es) 2021-12-10
JP7761614B2 (ja) 2025-10-28
JP2022530397A (ja) 2022-06-29
AU2020263238A1 (en) 2021-11-04
NZ781127A (en) 2025-06-27
CN119700968A (zh) 2025-03-28
MA55756A (fr) 2022-03-02
ZA202108094B (en) 2025-05-28
IL286818B2 (en) 2026-03-01
AU2020263238B2 (en) 2023-08-17
AU2023265759A1 (en) 2023-12-07
IL286818B1 (en) 2025-11-01
IL286818A (en) 2021-10-31
CA3134587A1 (en) 2020-10-29
SG11202110619XA (en) 2021-11-29
JP7297930B2 (ja) 2023-06-26
TWI850365B (zh) 2024-08-01
JP2023116680A (ja) 2023-08-22
WO2020219314A1 (en) 2020-10-29
KR20250153865A (ko) 2025-10-27
EP3958897A1 (en) 2022-03-02
UA128657C2 (uk) 2024-09-18
KR102869852B1 (ko) 2025-10-14
TW202515610A (zh) 2025-04-16
BR112021018930A2 (pt) 2022-01-18
TW202103734A (zh) 2021-02-01
US20220040299A1 (en) 2022-02-10
AU2020263238C1 (en) 2024-02-22

Similar Documents

Publication Publication Date Title
US20250034243A1 (en) Methods of treating ulcerative colitis
IL324048A (en) Mirikizumab for use in a method of treating crohn's disease
CA3134587C (en) Mirikizumab for use in a method of treating crohn's disease
EA045979B1 (ru) Мирикизумаб для применения в способе лечения болезни крона
HK40036550A (en) Mirikizumab in the treatment of ulcerative colitis
HK40036550B (en) Mirikizumab in the treatment of ulcerative colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination